Back to Search
Start Over
Protecting High-Risk Oncology Patients During the COVID-19 Pandemic by Creating an Isolated Outpatient Clinic.
- Source :
-
JCO oncology practice [JCO Oncol Pract] 2022 Apr; Vol. 18 (4), pp. e626-e631. Date of Electronic Publication: 2021 Dec 09. - Publication Year :
- 2022
-
Abstract
- Purpose: Delivering care for immunocompromised, high-risk patients with cancer during a pandemic has proven challenging. Patients with cancer on chemotherapy have a high risk of mortality if contracted COVID-19. If a patient goes directly to the emergency room, multiple contact points with other individuals can lead to unnecessary exposures from any airborne virus, such as COVID-19. Our cancer center has implemented an isolated clinic with personal protective equipment and direct access to a COVID-19 rule-out floor to manage those with febrile neutropenia (FN).<br />Methods: We implemented an outpatient, isolated, extended-hour clinic with access to personal protective equipment, laboratories, and antibiotics for patients with FN as a pilot project from April 1 to December 31, 2020, with the aim to decrease emergency department (ED) visits for FN by 50%.<br />Results: Since the implementation of our clinic, we have screened 74 unique patients during 102 visits, of which 76 led to a discharge and 26 led to a direct admit, thus avoiding the ED. Thirty-nine of these visits were for patients with recent travel or a known COVID-19 exposure. Bringing these patients to our isolated clinic ensured safety of the approximately 200 patients undergoing active treatment in our infusion center daily.<br />Conclusion: Implementing this clinic has thus far successfully decreased the social footprint of our highest-risk patients with cancer in the ED considerably. Our efforts and hopes of decreasing the possible exposure of our immunocompromised patients to COVID-19 as well as the unnecessary exposure of the infusion center patients and personnel have thus far been effective.<br />Competing Interests: Manidhar LekkalaStock and Other Ownership Interests: Pfizer, Editas Medicine¸ AbbVie, Teva, Atara Biotherapeutics Arpan PatelHonoraria: Medpage, AstraZeneca, Onc.AIResearch Funding: Onc.AI (Inst)No other potential conflicts of interest were reported.
Details
- Language :
- English
- ISSN :
- 2688-1535
- Volume :
- 18
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- JCO oncology practice
- Publication Type :
- Academic Journal
- Accession number :
- 34882499
- Full Text :
- https://doi.org/10.1200/OP.21.00126